FGF23 and chronic kidney disease: In models of CKD-MBD, metformin prevented an increase in serum creatinine, phosphate, PTH, and FGF23, and a decline in serum calcium in rats, with a consequent lower rate of high bone turnover disease and vascular calcification [45].